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Abstract 41 
Objective. To assess the evidence for treatment of oral involvement of pemphigus and pemphigoid with 42 
biologics. 43 
Study Design. This systematic review used a comprehensive search strategy to identify literature 44 
describing oral involvement of pemphigus or pemphigoid treated with a biologic agent. The primary 45 
outcome measures were efficacy and safety of biologic therapy. 46 
Results.  Inclusion criteria was met by 154 studies including over 1200 patients. Treatment of pemphigus 47 
with a total of 11 unique biologic agents and 3 unique combinations of agents is reported. Five randomized 48 
controlled trials (RCT) were included in the final analysis that investigated infliximab, IVIg, rituximab and 49 
autologous platelet-rich plasma therapy for pemphigus vulgaris. Three non-RCT studies reported on 50 
successful rituximab or IVIg therapy for mucous membrane pemphigoid. Studies demonstrated 51 
considerable heterogeneity in agent, methods, and quality. 52 
Conclusions. Evidence clearly describing oral tissue response to biologic therapy is sparse. Two RCTs 53 
support use of rituximab, one supports use of IVIg, and one pilot study suggests intralesional injection of 54 
autologous platelet-rich plasma aids healing of oral PV lesions. As oral lesions of pemphigus and 55 
pemphigoid can be refractory to systemic therapy, drug trials including biologic therapies should 56 
document details regarding response of the oral lesions to therapy. 57 
 58 
  59 
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Introduction 60 
Biologics have gained recognition as promising therapies for inflammatory and autoimmune 61 
disorders, and there is significant interest in evaluating the potential of this drug class for the treatment 62 
of complex oral disease. A biologic or biologic therapy is defined as a substance that is made from a living 63 
organism or its products to treat disease (NCI Cancer Dictionary). Strides have been made in the treatment 64 
of the autoimmune epidermal blistering disease pemphigus using biologics, and the United States Food 65 
and Drug Administration (FDA) approved the use of a biologic agent, rituximab, for the treatment of adults 66 
with moderate to severe pemphigus vulgaris (PV) in June 2018.  67 
Pemphigus consists of a group of autoimmune diseases characterized by epithelial blistering affecting 68 
cutaneous and/or mucosal surfaces. Intraepithelial blister formation results from the loss of adhesion of 69 
keratinocytes (acantholysis), with immunoglobulin G (IgG) antibodies directed against desmosomal 70 
proteins. PV is the most common and most aggressive variant (Baum et al., 2016). The oral mucosa is the 71 
site of initial presentation in 50-75% of cases (Mustafa, Porter, Smoller, & Sitaru, 2015; Robinson, Lozada-72 
Nur, & Frieden, 1997; Shamim, Varghese, Shameena, & Sudha, 2007).   73 
The complex pathogenesis of PV involves the generation of autoantibodies against connective 74 
proteins of the skin and mucosa including desmosomal cadherins (Saito et al., 2012). Desmoglein 3 is the 75 
major antigen, but 50–60% of patients also have anti-desmoglein 1 antibodies (Cozzani et al., 2013; 76 
Kasperkiewicz et al., 2017). The clear role of autoantibodies in PV pathogenesis suggests an important 77 
therapeutic role for targeted agents that block the generation or survival of autoreactive immune 78 
components (Ellebrecht & Payne, 2017). 79 
The mainstay of treatment of pemphigus is immunosuppressive therapy (Ahmed, 2001, 2007). 80 
Management consists of two main phases: induction of remission and maintenance of remission. For 81 
decades, systemic corticosteroids have been the therapy of choice for induction with maintenance 82 
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effected by azathioprine, mycophenolate mofetil, dapsone, methotrexate, cyclophosphamide, gold, and 83 
cyclosporine. Adjuvant techniques to reduce antibody load include plasmapheresis, and 84 
immunoadsorption (McMillan et al., 2015). Mucocutaneous PV tends to be a more severe disease, with 85 
oral lesions being slower to respond to treatment and less likely to achieve remission off-treatment than 86 
solely cutaneous disease(Kavusi et al., 2008). There have been recent international attempts to 87 
standardize the diagnosis and management of pemphigus, and newer therapies such as biologics or 88 
intravenous immunoglobulin (IVIg) therapy may offer significant advantages over systemic corticosteroids 89 
(Ellebrecht & Payne, 2017; Hertl et al., 2015; D. F. Murrell et al., 2018).  90 
Mucous membrane pemphigoid (MMP) is a rare, predominantly mucosal subepithelial blistering 91 
disorder involving the oral mucosa, conjunctiva, anogenital tissues, and upper aerodigestive tract. Wide 92 
variation in disease severity ranges from minimal painless oral involvement to severe blistering with 93 
scarring sequelae. Several basement membrane proteins are associated with autoantibody reactivity 94 
including BP180, BP230, both subunits of α6β4 integrin, laminin 332, and type VII collagen(Enno Schmidt 95 
& Zillikens, 2013). Mild disease is managed with topical steroids and moderate/severe disease with short-96 
term prednisone and long-term mycophenolate mofetil, azathioprine or dapsone (Taylor et al., 2015).  97 
 98 
Based upon the rationale that pemphigus and mucous membrane pemphigoid are primarily 99 
autoantibody-driven autoimmune disorders, therapies that deplete autoreactive B cells have been 100 
investigated for the treatment of these disorders (Nagel, Hertl, & Eming, 2009). Rituximab is a chimeric 101 
murine–human monoclonal antibody of the IgG1 subclass, directed against the B-lymphocyte-specific 102 
antigen CD20, expressed by early B cells in the bone marrow, autoantigen-specific B cells, memory B cells 103 
and mature B cells  (Nagel et al., 2009). Rituximab was first used to treat PV in the early 2000s in patients 104 
refractory to conventional treatment. By 2007, several case series had emerged showing efficacy (Ahmed, 105 
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Spigelman, Cavacini, & Posner, 2006; Joly et al., 2007; E. Schmidt, Seitz, Benoit, Brocker, & Goebeler, 106 
2007).  Following treatment with rituximab there is rapid and sustained (6–12 months) depletion of 107 
circulating and tissue-based B cells. Initial studies for dosing for rituximab in immunobullous disorders 108 
reflected a regimen derived from the treatment of patients with lymphoma, using four weekly infusions 109 
of 375mg/m2 (Joly et al., 2007). Since then, clinicians have adopted an alternate regimen: two infusions 110 
of 1000mg separated by two weeks (Y. A. Leshem et al., 2014; Yael A. Leshem, Hodak, David, Anhalt, & 111 
Mimouni, 2013). Advantages of this regimen include fewer infusions and a lower total dose of rituximab. 112 
Less data is available for rituximab use in MMP. 113 
The Seventh World Workshop in Oral Medicine sponsored this systematic review to evaluate the 114 
efficacy of biologic therapies in the management of pemphigus, including subtypes PV and Paraneoplastic 115 
pemphigus (PNP), and MMP involving the oral mucosa, with or without cutaneous lesions. The study 116 
summarizes the evidence supporting the use of biologics as first line, second line or adjuvant therapy in 117 
these conditions. This review also highlights the wide variation in clinical practice and the need for high-118 
quality research to validate current guidelines and to explore future therapies. 119 
 120 
Methods 121 
A systematic review was conducted following a detailed protocol. Key aspects of the protocol are 122 
summarised here. 123 
Inclusion Criteria 124 
Randomized controlled trials (RCTs), controlled clinical trials (CCTs), observational studies (e.g., cohort 125 
studies, case series and case reports) were included. Studies investigating biologic treatments for PV, PNP 126 
and MMP with oral involvement were included. Case reports, case series, meeting abstracts and clinical 127 
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observations were included only if there was a clear description of biologic therapy for patients with oral 128 
disease. 129 
Data from study participants were included if accepted criteria in all three diagnostic domains: clinical 130 
presentation, histology, and immunofluorescence was met and there was evidence of oral mucosal 131 
involvement and assessment.  132 
Exclusion criteria 133 
Studies describing only cutaneous disease, those that reported primarily on cancer therapy, papers with 134 
insufficient information about oral manifestations of disease or oral tissue response to therapy, non-135 
English papers, and full text unavailable papers were excluded. For duplicate reports or datasets 136 
identified, only the most final version of the paper was included.  Some studies included in the final 137 
dataset included a mixed disease cohort. Participants with cutaneous disease only or involvement at only 138 
non-oral sites were excluded from data extraction when individual patient response data were available. 139 
Types of interventions 140 
Active biologic treatment included any preventive, palliative, or curative intervention administered 141 
systemically aimed at the treatment of PV, PNP and MMP meeting the United States National Institutes 142 
of Health, National Cancer Institute definition of a biologic or biologic therapy: a substance that is made 143 
from a living organism or its products to treat disease. 144 
Types of outcome measures 145 
Primary outcome measures were efficacy and safety. Secondary outcome measures included time to 146 
disease control, time to disease relapse, disease severity score, serum antibody titers, and quality of life. 147 
Electronic searches 148 
Assisted by a research librarian (RP), MEDLINE® (via PubMed), Embase, Scopus and the Cochrane Library 149 
from date of database inception through October 26, 2018 were searched using general terms for 150 
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biologics, or terms for specific drugs or drug classes combined with terms for pemphigus, pemphigoid, or 151 
other related diseases. Either medical subject headings (MeSH) or Embase subject headings (Emtree) 152 
where available and keywords when applicable were used. Conference papers were searched in Embase 153 
and Scopus. The electronic search excluded all non-English language papers which did not have an English 154 
version. This study was structured according to PRISMA statement for reporting of systematic review and 155 
meta-analysis. 156 
Searching other resources 157 
We reviewed the bibliographies of RCTs and review articles and searched clinical trial databases 158 
(ClinicalTrials.gov (ClinicalTrials.gov) and World Health Organization (WHO) International Clinical Trials 159 
Registry Platform (ICTTRP) (apps.who.int/trialsearch/)) to identify additional published or unpublished 160 
data. We did not contact investigators or study sponsors. The detailed search strategy is provided in the 161 
online Supplementary Material Appendix 1. 162 
Selection of studies 163 
Abstracts of each search-identified study were evaluated by two authors who reached agreement for 164 
inclusion. Studies that clearly did not satisfy the inclusion criteria were eliminated, and full copies of the 165 
remaining studies were obtained. Two review authors (BPC, JWM) read the studies independently and 166 
reached agreement by discussion. Studies were not anonymized before assessment. Study tracking 167 
through the selection process was completed using Covidence systematic review software ("Covidence 168 
systematic review software,"). The flow of studies is illustrated in a PRISMA flow chart (Liberati et al., 169 
2009). 170 
Data extraction and management 171 
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One review author (BPC or JWM) extracted data independently, using a standard custom data extraction 172 
form for full studies (online Supplementary Material Appendix 2) and a short data extraction form for case 173 
reports and case series (online Supplementary Material Appendix 2) through Google Forms which 174 
concatenated results into a database. Forms were based on STROBE criteria (von Elm et al., 2008). Data 175 
extraction was cross-checked by the other author against the full manuscript.  176 
 177 
Assessment of risk of bias in included studies 178 
Two review authors (BPC, JWM) independently assessed then cross-checked and discussed the 179 
assessment of risk of bias for each RCT (n=5). The revised Cochrane tool to assess risk of bias in randomized 180 
trials (RoB 2) for individually-randomized, parallel-group trials (October 2018) was used to assess the RCTs 181 
across five domains: 1. Bias arising from the randomization process; 2. Bias due to deviations from 182 
intended interventions; 3.Bias due to missing outcome data; 4. Bias in measurement of the outcome; and 183 
5. Bias in selection of the reported result (Higgins JPT). Risk of bias for each domain was assessed as “high,” 184 
“low,” or “some concerns.” A study with one or more “high” risk of bias judgments for any given domain 185 
was deemed overall to have a high risk of bias.  186 
Data synthesis and measures of treatment effect 187 
Case reports and series were scored to evaluate the question, ”Was the therapy effective in managing the 188 
oral disease?” the outcomes of each study were categorized by reviewers during data extraction on a 4-189 
point scale: Completely Effective (in all patients), Mostly Effective in more than 50% of patients (not totally 190 
effective), Partially Effective (in less than 50% of patients treated with biologics--this option selected if 191 
data were unclear about %, but drug was not effective in all patients), or Ineffective in all patients. 192 
Effectiveness was based on the outcome criterion within the individual study. The category was assigned 193 
by one reviewer and confirmed by a second, and any disparity was settled through discussion. Studies 194 
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that included multiple types of pemphigus or pemphigoid diagnoses were excluded from this overview 195 
analysis, which limited the categorical summary to case reports and case series, as all other study types 196 
had mixed disease cohorts. The results are reported as percent of total reports for that drug and disease 197 
category. 198 
 199 
Results 200 
 201 
From 6416 unique records, we identified 165 studies including more than 1200 patients with oral 202 
involvement of pemphigus or pemphigoid treated with a biologic agent. Due to the emerging nature of 203 
this field, case reports and case series were included in this review and comprised 80% of the number of 204 
total publications and 47% of the overall patients (Figure 1). The remaining 29 full studies were comprised 205 
of 5 randomized controlled trials, and 24 non-randomized studies (3 non-randomized controlled trials, 14 206 
cohort studies, and 7 non-controlled trials). Specific biologic agent and dosing varied across studies and 207 
was variably reported. Studies included 11 unique biologic agents and 3 combination therapies. The 208 
breakdown of publication type by biologic therapy is shown in Figure 1b. MMP or PNP was not the topic 209 
of any identified RCTs. Most (135/154, 88%) of the included studies used biologics as salvage therapy in 210 
heavily-treated patients who were refractory to other modalities.  211 
Detailed analysis of the 5 RCTs for the treatment of pemphigus are summarized below and in 212 
Table 1. Four studies were classified as parallel RCTs (Joly 2017, Hall 2015, Kanwar 2014, Amagai 2009) 213 
and one was a ‘split-mouth’ RCT (El-Komy 2018). Three of the studies were multicenter (Joly 2017, Hall 214 
2015, Amagai 2009). Two of the RCTs used placebo controls (Hall 2015, Amagai 2009) but allowed both 215 
groups to continue some form of active pharmaceutical intervention (i.e. systemic steroids). All the RCTS 216 
used clinical outcome measures, however, there was considerable heterogeneity in the specific outcome 217 
measures employed.  Reduced dosage of corticosteroids and PV antibody titers were used as surrogate 218 
markers for treatment efficacy in several studies. Because of the heterogeneity of outcomes for each of 219 
the studied interventions, quantitative meta-analysis could not be conducted. Analyses of the relevant 220 
WWOM VII: Biologics for pemphigoid and pemphigus     Page 10 
 
outcomes (relative risks and 95% CIs) from the RCTs are summarized in detail below. A quality assessment 221 
of included randomized controlled trials was performed using Cochrane Risk of Bias (RoB 2.0) and is 222 
detailed in Supplemental Figure 1. 223 
Rituximab was tested in 2 RCTs that included assessment of the oral mucosa. Kanwar et. al. 224 
conducted randomized comparative observer-blinded pilot study that compared two rituximab dosing 225 
regimens for the treatment pemphigus (Kanwar et al., 2014). Patients with active PV (n=15) or PF (n=7) 226 
who were treatment-naive, resistant to previous therapies, or who had severe disease were recruited 227 
from a dermatology department in a tertiary care setting in India. They were randomized to receive either 228 
two doses of 500 or 1000 mg rituximab at an interval of 15 days and were followed for 48 weeks. The 229 
primary endpoint was clinical efficacy between treatments in terms of early (time to disease control and 230 
time to complete consolidation phase) and late end points [partial response (PR) and complete response, 231 
(CR)] on the Ikeda severity score scale as assessed by an examiner blinded to treatment group (Ikeda et 232 
al., 2003). No significant adverse events (SAEs) were recorded in either group, though AEs including mild 233 
infusion reactions, upper respiratory tract infections, diarrhea, striae and acneiform eruptions were seen 234 
in both groups. The mean number of AEs was 1.36 in the 2x500 mg group and 1.45 in the 2x1000 mg 235 
group. At week 40, the fall in Ikeda severity score was steeper in the 2x1000 mg group than in 2x500 mg 236 
group (P = 0.049). Patients in the 2x500 mg group received a significantly higher cumulative dose of 237 
azathioprine (P = 0.018). ELISA indices of Dsg1 and Dsg3 showed a statistically significant decline in the 238 
2x1000 mg group only, and B cell repopulation occurred earlier 8 weeks earlier in the 2x500 mg group. 239 
In 2017, Joly and colleagues published results from an open-label multicenter parallel RCT 240 
comparing oral prednisone alone versus rituximab and a short-term prednisone regimen to treat newly-241 
diagnosed pemphigus (Joly et al., 2017). Pemphigus patients with PV (n=74) or PF (n=16) were recruited 242 
at 25 centers in France and randomized to one of 2 groups: oral prednisone alone starting at 1.0 or 1.5 243 
mg/kg/day, tapered over 12-18 months (n=44) , or  1000 mg intravenous rituximab on days 0 and 14, and 244 
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a 500 mg dose at months 12 and 18 combined with a short-term prednisone treatment of 1.0-245 
1.5mg/kg/day tapered over 3-6 months (n=46). Stratification by severity of pemphigus was included in 246 
the randomization matrix, and moderate-to-severe pemphigus was defined as skin involvement of greater 247 
than 5% body surface area, or significant mucosal involvement defined as more than ten mucosal 248 
erosions, or diffuse gingivitis or confluent large erosions, or involvement of two or more mucosal sites. 249 
Scoring of the oral mucosa was incorporated into the mucous membrane subsection of the Pemphigus 250 
Disease Area Index (PDAI) scoring tool, however, oral tissue subscores were not reported for this study 251 
(Dedee F. Murrell et al., 2008). Patients assigned to rituximab plus short-term prednisone had significantly 252 
fewer SAEs (mean 0·59 [SD 1.15]) than patients those assigned to prednisone alone (mean 1.20 [SD 1·25]), 253 
which was attributed to the lower cumulative steroid dose in the rituximab group. At the primary 254 
endpoint, month 24, 41 (89%) of 46 patients assigned to rituximab plus short-term prednisone were in 255 
complete remission off-therapy versus 15 (34%) of 44 assigned to prednisone alone (p<0·0001). The 256 
corresponding relative risk of success of is 2.61 (95% CI 1·71–3·99, p<0·0001). Data from this study 257 
demonstrate a clear benefit of rituximab as a first-line therapy for pemphigus patients, including those 258 
with severe oral mucosal manifestations. 259 
Inflammation is a significant factor in the feed-forward circuit of autoimmune disease. Tumor 260 
necrosis factor alpha (TNF-α) is cytokine that has been detected in the skin lesions of patients with PV, 261 
and serum levels of TNF-α have been correlated with disease activity. In 2015, Hall et al. reported 262 
treatment of pemphigus patients using infliximab, an inhibitor of TNF-α (Hall et al., 2015). This double-263 
blinded, placebo-controlled trial was carried out at 6 centers in the United States. Ten patients received 264 
infusions of infliximab (5 mg kg) at weeks 0, 2, 6 and 14 while receiving standard-of-care with follow-up 265 
at weeks 10, 18, 22 and 26. Ten control group patients received infusions of placebo at weeks 0, 2, 6 and 266 
14 while receiving prednisone with follow-up at weeks 10, 18, 22 and 26. To qualify for the study, patients 267 
were required to score moderate or severe on both the mucosal and cutaneous subsections of a disease 268 
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activity score. For the mucosal subsection, a moderate score required 6–10 lesions/small ulcers. This scale 269 
was used for clinical scoring at each study visit. In this trial, the primary endpoint was defined as response 270 
to treatment at week 18. Subjects were responders if they achieved a prednisone dosage ≤ 25% of the 271 
initial starting dose or ≤ 10 mg daily and had no new blisters within the previous 4 weeks. Groups did not 272 
differ in AE incidence, and no infectious complications of Grade 3 or greater (Common Terminology 273 
Criteria for Adverse Events, CTCAE 3.0) were reported (Trotti et al., 2003). At the primary endpoint, week 274 
18, one subject in each group had responded. At week 26, three infliximab-treated subjects versus none 275 
in the placebo group had responded. Assessment of IgG anti-Dsg1 and anti-Dsg3 antibody titers found 276 
significantly lower levels in infliximab-treated patients at week 18 and 26. Study authors concluded that 277 
infliximab therapy was not shown to be clinically effective for the treatment of patients with PV. 278 
Intravenous immunoglobulin (IVIg) is used as an adjuvant steroid sparing agent in PV or as a 279 
monotherapy. It is a purified product consisting mostly of IgG molecules made from a pool of donors and 280 
is thought to have multiple mechanisms of action including downregulation of antibody production by 281 
plasma cells (Hartung, 2008). Amagai and colleagues conducted a three-arm clinical trial to test two doses 282 
of IVIg versus placebo using a new outcome measure, time to escape protocol (length of time participant 283 
stayed on protocol without requiring additional treatment up to day 85, TEP) (Amagai et al., 2009). 284 
Pemphigus patients, including PV (n=40) and PF (n=21), received a 200mg IVIg, 400mg IVIg, or placebo 285 
infusion administered in divided doses over 5 days plus oral steroids. TEP was the primary endpoint of the 286 
study. Secondary endpoints included change in pemphigus activity score (PAS) which specifically scores 287 
oral mucosal and skin lesions. At day 85, AEs, called adverse drug reactions in this study, occurred in 29% 288 
of the 400mg group, 35% of the 200mg group and 25% of the placebo group, with no statistical differences 289 
between groups. By day 85, 11/20 patients on placebo required elevated treatment (escape), 4/20 290 
patients in the 200mg IVIg group escaped after 10+ days, and 2/21 patients on 400mg IVIg escaped after 291 
22+ days. A log-rank test was used to compare treatment groups to placebo only and found a significant 292 
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change in TEP between placebo and the 400mg group (p<0.001). The PAS, which included mucosal scoring, 293 
was significantly changed (decreased) from baseline at all time-points in the 400mg group, after day 15 294 
only in the 200mg group, and not significantly changed in the placebo group. Similarly, anti-Dsg1 and Dsg3 295 
IgG titers were decreased at day 43 and 85 in the 400mg group, at day 85 only in the 200mg group, and 296 
not at all in the placebo group. 297 
Direct therapy may be applied to isolated oral lesions or those refractory to systemic treatment. 298 
Autologous platelet-rich plasma (PRP) has been used locally to accelerate cutaneous and oral wound 299 
healing, and to treat refractory oral ulcers in autoimmune conditions (Bojanic et al., 2018; Lacci & Dardik, 300 
2010).  In 2018, El-Komy et. al. reported a pilot single center randomized double-blind study comparing 301 
local injection of PRP on one side of the mouth with active standard treatment: local injection of 302 
triamcinolone acetonide on the contralateral side (El-Komy, Saleh, & Saleh, 2018). The trial was conducted 303 
in an Egyptian hospital in 11 PV patients with oral pain or oral lesions. Buccal mucosa or gingiva was 304 
injected every 14 days for 3 months with 1 milliliter of autologous PRP at the base and side of the erosion, 305 
and on the opposite side with 10 mg/ml triamcinolone. Patient and scoring physician were blinded to the 306 
treatment assignment. Scoring was completed per the oral PDAI for the primary endpoint of oral lesion 307 
improvement after 90 days. No AE summary was provided for the study. Nine patients completed the 308 
study, and triamcinolone injection decreased the mean oral PDAI from 2.3 to 0.9, and PDAI scores after 309 
PRP injection moved from 2.6 to 1.0. Statistically equivalent clinical improvement was measured when 310 
refractory oral ulcers of PV were injected with either steroid or PRP.  311 
MMP patients were included in 1 non-randomized controlled trial and 2 cohort studies that used 312 
IVIg treatment, 2 cohort studies that examined rituximab treatment (Table 1).  Sami et. al. reported on 7 313 
severe oral pemphigoid patients treated with IVIg therapy versus 7 similar patients on standard therapy 314 
(N. Sami, Bhol, & Ahmed, 2002). The primary outcome was change in the anti-human alpha6 integrin 315 
antibody titers, which have a pathophysiologic role in blister formation in OP. Titers in the IVIg group 316 
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dropped at a similar rate to controls through month 4 of treatment, but then declined at a significantly 317 
faster rate after six months of treatment (P = 0.03). A case series that examined patients with autoimmune 318 
mucocutaneous blistering diseases on monthly courses of IVIg included 4 MMP patients (Segura et al., 319 
2007). One had a complete clinical response, 2 had a partial response and 1 did not respond to treatment. 320 
Steroid refractory MMP patients (n=15) were treated with IVIg in a separate non-controlled study (Naveed 321 
Sami, Bhol, & Razzaque Ahmed, 2002). All (15/15) patients had effective clinical response and were able 322 
to discontinue previous systemic therapies, with no reported AEs. Salvage therapy with rituximab has 323 
been reported in 4 patients across 2 case series that included MMP patients (Kolesnik et al., 2014; E. 324 
Schmidt, Seitz, Benoit, Bröcker, & Goebeler, 2007). One patient had clinical progression of MMP (51) on 325 
rituximab combined with immunoadsorption, 2 patients achieved a complete response (reduction in dose 326 
of systemic immunosuppression) after several (number varied) rituximab infusions, and 1 patient had a 327 
partial response.  328 
Scoring of the case reports and case series in the dataset was done to answer, “was the therapy 329 
effective in managing oral disease?” Results of each study were categorized as: Completely Effective (in 330 
all patients), Mostly Effective in more than 50% of patients (not totally effective), Partially Effective (in 331 
less than 50% of patients treated) or Ineffective in all patients. In the case studies and series using 332 
rituximab in pemphigus vulgaris with oral involvement (n=48), rituximab was Completely Effective in 333 
managing oral disease in 40% of cases and Mostly Effective in 48% of cases. It was Partially Effective or 334 
Ineffective in 6% each of case reports or series. For MMP (n=11), rituximab was Completely Effective in 335 
45% of cases, Mostly Effective in 27% of cases and Partially Effective in 27% of cases. A wider response 336 
distribution is noted in cases of PNP treated with rituximab (n=14), in which 29% of cases were Completely 337 
Effective, 21% of cases were Mostly Effective, 21% were Partially Effective, and rituximab was Ineffective 338 
for PNP in 29% of cases. IVIg was reported to be Completely Effective for treatment of MMP in all case 339 
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reports or series (n=6). For PV (n=11), IVIg was Completely Effective in 9% of cases, Mostly Effective in 340 
64% of cases, Partially Effective in 18% of cases and Ineffective in 9% of cases. 341 
 342 
Discussion 343 
In this systematic review, we assess the evidence base for treating oral manifestations of 344 
pemphigus and pemphigoid with biologics. The literature which clearly describes response to biologic 345 
therapy in the oral tissues affected by pemphigus and pemphigoid is sparse, and randomized controlled 346 
studies are thus far limited to the treatment of pemphigus. Five RCTs were identified by the search 347 
parameters, along with 24 other non-controlled or non-randomized studies using biologic agents to treat 348 
pemphigus or pemphigoid. Two RCTs support use of rituximab to reduce total cumulative corticosteroid 349 
dose and associated side effects. One trial that included heterogenous group of new-onset and refractory 350 
patients found that higher doses of rituximab (two doses of 1000 mg at a 15-day interval) were more 351 
effective. A second RCT treated new-onset PV patients only with a modified rituximab regimen of 1000 352 
mg on days 0 and 14, and 500 mg at months 12 and 18 along with a steroid pulse, and at 24-months on 353 
study, 89% of rituximab-treated patients were in full remission (off therapy) while only 34% of steroid-354 
only-treated patients were off therapy for pemphigus. Unfortunately, limited specific information was 355 
available from these trials regarding oral mucosal response to rituximab therapy. The trial of IVIg included 356 
patients with moderate-severe oral mucosal lesions and found that 400mg doses of IVIg were superior to 357 
placebo in preventing pemphigus flares requiring escalated therapy. Finally, one small pilot study suggests 358 
that intralesional injection of autologous platelet-rich plasma may aid in healing of oral PV lesions when 359 
intralesional steroids are contraindicated, equivalent to triamcinolone acetonide injection, however 360 
significant concerns exist with the small size and design of this study – specifically that agents given on 361 
one side of the mouth may have affected lesions on the contralateral side. Results of infliximab therapy 362 
for pemphigus found that it neither reduced systemic prednisone dosage required nor reduced 363 
occurrence of new lesions. The four agents investigated in RCTs: rituximab, infliximab, IVIg, and PRP had 364 
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equivalent safety profiles to that of control agents, generally standard-of-care steroid regimens, in the 365 
studies.  366 
Any analysis of the case reports and case series included in this literature survey is inherently 367 
biased and should be interpreted with caution, as single case studies are rarely published to report 368 
treatment failures. IVIg and rituximab are the most reported agents in these papers, and those agents 369 
have been tested in some form of RCT for pemphigus. They have performed well, but with lower success 370 
rates than suggested by the case reports/series descriptive analysis. 371 
Data from the Joly 2017 study was the basis for the United States FDA approval of the use of 372 
rituximab for the treatment of adults with moderate to severe pemphigus vulgaris (PV) in mid-2018. 373 
Additional trials are in progress and it is anticipated that treatment of PV with rituximab will soon be 374 
better described in the literature. 375 
New targeted therapeutic agents are in development for treatment of pemphigus that could 376 
further limit side-effects through more precise targeting of autoimmune pathobiology. These include 377 
chimeric antigen receptor therapy to target anti-desmoglein-3-specific B cells that produce pathogenic 378 
pemphigus autoantibodies (Ellebrecht et al., 2016), blockade of T-cell co-receptors such as CD154 that are 379 
required by B cells for stimulation of autoantibody production, and a Bruton’s tyrosine kinase (BTK) 380 
inhibitor that is in active clinical trials for PV (Principia Biopharma, 1993–2018), among other promising 381 
strategies.  382 
Another emerging nuance of this field that is beyond the scope of this review are the reports of 383 
oral bullous lesions induced by biologic therapies (Naidoo et al., 2016; Vigarios, Epstein, & Sibaud, 2017). 384 
These may occur after checkpoint inhibitor or other biologic therapy for myriad conditions and can 385 
present with a standard serologic and histologic profile of pemphigus or pemphigoid. These cases are 386 
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typically addressed with interruption of biologic therapy and initiation of systemic and topical steroids but 387 
may need differential clinical management versus non-drug-induced bullous disease.   388 
Oral lesions of pemphigus and pemphigoid can be refractory to systemic therapy, and in this 389 
emerging drug class, it is critical to report on the timing and response of the oral cavity to biologic therapy 390 
from clinical trials to aid in the clinical decision-making process for patients with severe or primarily oral 391 
manifestations of bullous disease. Evidence is missing from the literature that could guide earlier 392 
recommendations for biologic therapy to address problematic oral manifestations. Given the challenges 393 
of treating these conditions, it would be helpful for future RCTs and case-control studies to (1) include an 394 
oral-specific scale or report on oral mucosal outcomes that are often scored as part of comprehensive 395 
scales such as the PDAI and Autoimmune Bullous Skin Disorder Intensity Score (ABSIS), (2) track and report 396 
timing of disease resolution at specific sites (oral vs ocular vs skin), (3) describe site-specific symptoms 397 
including oral symptoms and the timing of response of these to biologic (or other) therapies, (4) include 398 
patient-reported outcomes tracking better or worse control of pain and discomfort at mucosal sites and 399 
tolerance of biologics versus traditional therapies.  400 
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Table 1 571 
 572 
Study Year 
Interv
ention Country 
Study 
Type 
No of 
sites 
No of 
patients 
Sex, 
M:F 
Age 
(yr) Disease 
Disease 
Status 
Disease 
Duration 
(mean) 
Biologic 
Dose Adverse Effects 
Joly et 
al 
2017 Rituxi
mab 
France RCT 25 90 40;50 53.3 Pemphigu
s vulgaris, 
pemphigu
s 
foliaceus 
Initial 97.8 days 1000mg 
day 1 and 
14, then 
500mg at 
12m and 
18m 
Headache, 
asthenia, fever, 
chills, nausea, 
septicemia, 
pyelonephritis, 
death 
Hall et 
al 
2015 Inflixi
mab 
USA RCT 6 20 12;8 53.25 Pemphigu
s vulgaris 
Refractory Not stated 5mg/kg at 
weeks 0, 2, 
6 and 14 
No infectious 
complications 
Kanwa
r et al 
2014 Rituxi
mab 
India RCT 1 22 11;11 33.4 Pemphigu
s vulgaris, 
pemphigu
s 
foliaceus 
and 
pemphigu
s 
erythemat
osus 
Refractory 20.2 
months 
500mg or 
1000mg, 
two doses, 
2 weeks 
apart 
Infusion 
reactions, upper 
respiratory tract 
infections, 
diarrhoea, stria, 
acneiform 
eruptions 
Amaga
i et al 
2009 IVIG Japan RCT 27 61 27;34 53.36 Pemphigu
s vulgaris, 
pemphigu
s 
foliaceus  
Refractory 24.4 
months 
200mg or 
400mg/kg/d
, divided 
over 5 
consecutiv
e days 
Headache, 
aggravated 
chronic hepatitis 
C, decreased 
lymphocytes, 
palpitations, 
abdominal 
discomfort, 
constipation, 
nausea, pain at 
the injection site, 
increased 
creatinine, 
increased blood 
pressure, 
decreased 
platelet count, 
hepatic 
dysfunction, 
common cold, 
muscle pain.  
El‐
Komy 
et al 
2018 Platel
et rich 
plasm
a 
Egypt Split-
mouth 
RCT 
1 11 4;7 41.1 Pemphigu
s vulgaris 
Refractory 4mo - 8 
years 
1ml 
intralesiona
l PRP 
every 14 
days for 3 
months 
None 
Kolesni
k et al 
2014 Rituxi
mab 
German
y 
Cohort 1 3 2;1 68.7 Mucous 
membran
e 
pemphigoi
d 
2 
refractory, 
1 no prior 
treatment 
35.3 
months 
375 mg/m² 
at weekly 
intervals x 
4 
Infection in 1 
case 
Schmid
t et al 
2007 Rituxi
mab 
German
y 
Cohort 1 1 M=1 78 Mucous 
membran
e 
Refractory 64 
months 
375mg/m2 
at weekly 
intervals x 
4 
None 
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pemphigoi
d 
Segura 
et al 
2007 IVIG Spain Cohort 1 4 3 
female, 
1 not 
defined 
70.8 Mucous 
membran
e 
pemphigoi
d 
Refractory 88.5 
months 
2 
g/kg/cycle 
over 4 or 5 
consecutiv
e days 
Cephalea, 
hypertension, 
epitaxis, 
headache, fever, 
N+V+D 
Sami 
et al 
2002 IVIG USA Non-
random
ised 
trial 
1 7 2;5 55.5 Mucous 
membran
e 
pemphigoi
d 
Contraindi
cation to 
immunosu
ppressive 
therapy 
Not stated 1–2 
g/kg/cycle 
infused 
over 3 
consecutiv
e days 
None 
Sami 
et al 
2002 IVIG USA Cohort 1 15 7;8 66 Mucous 
membran
e 
pemphigoi
d 
Refractory Not stated 1–2 
g/kg/cycle 
infused 
over 3 
consecutiv
e days 
No side effects 
reported 
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